Skip to content
Open access

FlexAutoDock: A Flexible Platform for Automated Molecular Docking and Virtual Screening of Natural and Synthetic Compounds

Aug 2026 · bioRxiv · 0 citations · 34 references
Biology

TL;DR

FlexAutoDock is an automated cloud-based molecular docking platform that provides a unified environment for protein-ligand docking and large-scale virtual screening, providing researchers with an accessible computational resource for accelerating early-stage drug discovery.

Abstract

Drug discovery (DD) is a complex, time-consuming, and resource-intensive process that involves the identification of therapeutic targets, selection of bioactive compounds, and extensive experimental validation. The discovery of promising therapeutic compounds from large libraries of phytochemicals and synthetic molecules remains a major challenge in modern drug development. Screening millions of compounds through conventional experimental approaches requires substantial time, cost, and computational resources. In recent years, in- silico molecular docking has emerged as an important computational approach for predicting interactions between small molecules and target proteins, thereby helping researchers prioritize promising compounds for further investigation. Several molecular docking webservers, including iScreen, SwissDock, CB-Dock2, DockThor, and MTiOpenScreen, have been developed to support virtual screening studies. However, many currently available platforms still face some important limitations. Most existing tools lack integrated repositories of medicinal plant-derived phytochemicals and organism-derived bioactive compounds, automated mapping between plants and their associated phytochemicals, and flexible ligand retrieval using chemical names, SMILES strings, PubChem CIDs, or drug names. In addition, many platforms require extensive manual protein and ligand preparation, provide limited support for AlphaFold-predicted protein structures, and lack efficient large-scale multi-target virtual screening. Most existing docking platforms offer limited support for interactive inspection of docked protein-ligand complexes, often requiring users to download the results and analyse them using external molecular visualization software. To address these limitations, we developed FlexAutoDock, an automated cloud-based molecular docking platform that provides a unified environment for protein-ligand docking and large-scale virtual screening. Unlike existing web servers, FlexAutoDock integrates curated repositories of medicinal plant- derived phytochemicals, organism-derived bioactive compounds, and synthetic compounds from the ZINC database while supporting flexible ligand acquisition through medicinal plant or organism selection, chemical names, SMILES strings, PubChem CIDs, and drug-name queries. The platform further streamlines the docking workflow through automated protein structure retrieval from the Protein Data Bank and AlphaFold databases, receptor and ligand preparation, chain-specific protein selection, blind and site-specific docking, interactive visualization of predicted protein-ligand complexes, and scalable multi-target virtual screening. The resulting platform enables rapid, flexible, and large-scale virtual screening while simplifying the molecular docking workflow, providing researchers with an accessible computational resource for accelerating early-stage drug discovery. FlexAutoDock offers a fast, reliable, and accessible computational platform for molecular docking and virtual screening, freely available to the scientific community at http://103.99.177.82:3000/.

Read PDF

Similar papers

Review Open access Jul 2026

Natural Products in Modern Drug Discovery: Advances, Challenges and Emerging Technologies

Drug discovery is a complex and resource-intensive process, with lead identification representing a major bottleneck due to high attrition rates. Natural products have long served as a valuable source of structurally diverse and biologically active compounds, offering advantages such as evolutionary optimization, target specificity, and unique chemical diversity. This review provides a comprehensive and mechanistic overview of natural products as lead compounds, emphasizing their chemical characteristics, biological relevance, sources, mechanisms of action, and integration into modern drug discovery pipelines. A narrative review was conducted using major scientific databases (PubMed, Scopus, Web of Science, and Google Scholar), covering literature from 2000 to 2026. Relevant studies were selected based on scientific rigor and contribution to key themes, including natural product diversity, discovery strategies, and technological advancements. Natural products exhibit superior structural complexity and occupy unique chemical space compared to synthetic compounds, enabling effective interaction with diverse biological targets and supporting polypharmacological activity. Key sources include plants, microorganisms, and marine organisms, which have yielded numerous clinically important drugs. Advances in analytical techniques, genome mining, metabolomics, synthetic biology, and artificial intelligence have significantly improved discovery and optimization processes. Despite challenges related to complexity and scalability, natural products remain indispensable in drug discovery, with emerging technologies enhancing their potential for addressing unmet medical needs.

S. Papadopoulou, Efthymios Poulios, Fotios Tsopelas et al. · 2 citations
Sep 2026

Performances and Critical Limitations of Docking and Protein–Ligand Interactions for Efficacy-Driven Virtual Screening Targeting Class A GPCRs

Structure-based virtual screening of chemical libraries is an established and widely used strategy for identifying novel ligands for G-protein-coupled receptors. An enhancement based on integrating protein–ligand interaction with docking has previously been proposed, but its actual impact on improving screening outcomes has remained unclear. Here, we present a comprehensive assessment based on systematic benchmarking using a diverse set of class A G-protein-coupled receptors and different approaches to represent protein–ligand, including dynamic patterns extracted from molecular dynamics simulations. Our results demonstrate that the combined approach overall improves the efficacy bias of selected ligands as compared to docking alone (ranking by scoring function). All tested variations prove broadly functional; however, the most sophisticated one─incorporating simulation and a learning model─emerges as the most robust alternative for a prospective setting. The analysis of two prospective cases, the design of both agonists and antagonists of CNR1 and the more challenging search for CXCR4 nonpeptidic agonist, reveals both great potential and inherent structural limitations, highlighting the need for an accurate and suitable three-dimensional structure.

Luca Chiesa, G. Bret, Severine Schneider et al. · 0 citations
Open access Jul 2026

Prioritizing neuroactive ligands using motif-guided virtual discovery and zebrafish profiling

Virtual screening of ultra-large chemical libraries is a highly effective strategy for early-stage ligand discovery. However, these pipelines often yield thousands of molecules that pass computational filters, and in silico-derived interaction energies do not consistently predict experimental efficacy. Furthermore, many high-affinity hits do not necessarily function effectively in an organism with tissues, barriers, and extensive off-target possibilities. Here, we establish and apply an integrated pipeline that prioritizes candidate molecules through structure-guided computation and zebrafish-based functional profiling. We introduce Rosetta Engine for Anchoring Ligands with a Motif (“REAL-M”), a screening algorithm that uses structural interaction data from the Protein Data Bank (PDB) to guide ligand placement and selection. Using the hypocretin receptor as a test case, 28 of 30 predicted antagonists significantly blocked binding of the cognate peptide agonist in a cell-based reporter assay, including six chemically diverse molecules with efficacy comparable to preexisting antagonists. Three of these six significantly mitigated hypocretin-induced larval zebrafish hyperactivity. Secondary testing with a zebrafish hcrtr2 null mutant ensured that behavioral phenotypes were on target, in contrast to off-target phenotypes observed with a clinically approved antagonist. This pipeline is readily adaptable to the thousands of zebrafish proteins with highly conserved binding pockets.

Ari B. Ginsparg, Jaqueline A. Martinez, Ishaan Patel et al. · 0 citations
Open access Sep 2026

An extension of jamdock-suite for virtual screening from raw chemical datasets.

Virtual screening of chemical libraries has long been a cornerstone for identifying candidate bioactive compounds. Recently, many tools have been developed to make virtual screening more accessible. Among them, the jamdock-suite provides an automated and user-friendly workflow that encompasses the entire process from library generation to docking evaluation. However, its library generation is restricted to the ZINC database and cannot process user-supplied chemical datasets. Here, we present semdock, an extension of the original workflow that enables the preparation of docking-ready ligands from raw SDF, SMILES, and CSV datasets through an automated ligand preparation procedure. The workflow was validated using 3,230 FDA-approved compounds and multiple protein targets. We also implemented ligand-wise CPU-parallel docking, reducing runtime by approximately 30% compared with conventional multithreaded execution. Evaluation across multiple protein targets confirmed that the extended workflow preserves the utility of the original framework while expanding its use to diverse public and user-defined datasets.

Unknown authors · 0 citations
Open access Aug 2026

A Comprehensive Study Utilizing QSAR, Virtual Screening, Molecular Docking, Molecular Dynamics, and MM/GBSA Analyses Reveals Natural Diterpenoids as Promising Caspase-1 Inhibitors

This study highlights natural diterpenoids and coumarin glycosides as promising scaffolds for caspase-1 inhibition and demonstrates that integrating QSAR modeling with structure-based approaches provides an efficient strategy for discovering potential anti-inflammatory drug candidates.

Yusuf Şeflekçi, Alper Yılmaz, Abdulilah Ece · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.